On June 20, 2019, Whitefort Capital Management, LP filed a petition against Novelion Therapeutics Inc. as respondent, in the Supreme court of British Columbia seeking (i) a declaration that the Company has breached section 301 of the Business Corporations act of British Columbia, (ii) an order pursuant to section 301 of the BCA requiring the Company to hold a special meeting of its shareholders to vote on whether the Company should dispose of the Novelion Intercompany Loan to Aegerion Pharmaceuticals, Inc. pursuant to the terms of a voluntary restructuring support agreement entered into by the Company on May 20, 2019 in connection with the chapter 11 plan of reorganization for Aegerion in the united states bankruptcy court, southern district of new york case No. 19-11632 and (iii) an order pursuant to section 301 of the BCA providing that unless and until the shareholders of the Company vote to approve the disposition of the Novelion Intercompany Loan pursuant to the terms of the restructuring support agreement at the special meeting, the Company be enjoined from consummating such disposition transaction, and further that the Company be required to vote its claim against any plan of reorganization, in accordance with the disclosure statement and solicitation materials approved by the bankruptcy court.